a 2023

CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia.

PESCHELOVÁ, Helena, Veronika KOZLOVÁ, Veronika MANČÍKOVÁ, Lenka DOSTÁLOVÁ, Adriana LADUNGOVÁ et. al.

Basic information

Original name

CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia.

Authors

PESCHELOVÁ, Helena (203 Czech Republic, belonging to the institution), Veronika KOZLOVÁ (203 Czech Republic, belonging to the institution), Veronika MANČÍKOVÁ (703 Slovakia, belonging to the institution), Lenka DOSTÁLOVÁ (203 Czech Republic, belonging to the institution), Adriana LADUNGOVÁ (703 Slovakia, belonging to the institution), Dominika ŠKRNOVÁ (203 Czech Republic, belonging to the institution), Václav HEJRET (203 Czech Republic, belonging to the institution) and Michal ŠMÍDA (203 Czech Republic, guarantor, belonging to the institution)

Edition

PhD and PostDoc RETREAT, Sněžné, Milovy, 2023

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30204 Oncology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

RIV identification code

RIV/00216224:14740/23:00132849

Organization unit

Central European Institute of Technology

Keywords in English

Chronic lymphocytic leukemia; somatic mutations; CRISPR/Cas9 screening

Tags

Tags

Reviewed
Změněno: 30/3/2024 14:06, Mgr. Eva Dubská

Abstract

V originále

Chronic lymphocytic leukemia (CLL) is characterized by genetic heterogeneity and a variety of somatic mutations, the most frequent of which targeting ATM, TP53, NOTCH1, MYD88 and SF3B1 genes. A thorough exploration of these mutations could shed light on the disease etiology, or even lead to the discovery of potential novel drug targets. However, CLL cells extracted from patients do not proliferate ex vivo and thus preclude lengthy experiments, such as CRISPR/Cas9 screening. 76 The aim of this study was to generate stable knockout (ATM, TP53) and knock-in (NOTCH1, SF3B1 and MYD88) CLL cell lines and subsequently use them to investigate unique vulnerabilities specific to these mutations

Links

LX22NPO5102, research and development project
Name: Národní ústav pro výzkum rakoviny (Acronym: NÚVR)
Investor: Ministry of Education, Youth and Sports of the CR, National institute for cancer research, 5.1 EXCELES
MUNI/A/1224/2022, interní kód MU
Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit X
Investor: Masaryk University